Trial Profile
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 07 Mar 2016 According to ClinicalTrials.gov record, the age range for the patients has changed from 18-57 to 18-65, hence excluding elderly people.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.